NCT07396441RecruitingPhase 4
Supplementary Kelulut Honey Therapy in Juvenile Open-Angle Glaucoma: Effects on IL-6, RNFL and Dry Eye
Supplementary Kelulut Honey Therapy in Juvenile Open-Angle Glaucoma: Effects on IL-6, RNFL and Dry Eye.
Source: ClinicalTrials.gov · Last updated 9 Feb 2026
Brief summary (registry, in English)
The goal of this clinical trial is to evaluate the effects of stingless bee honey (Kelulut honey) in juvenile open-angle glaucoma patients. The study evaluates the effects on serum Interleukin 6 level(IL-6), retinal nerve fiber layer(RNFL) thickness and dry eye-related symptoms. A total of 60 participants who meet the study criteria will be randomly assigned to one of two groups. One group will consume 30 grams of Kelulut honey daily for a period of three months, while the control group will not receive honey or a placebo. Serum IL-6 level, RNFL thickness, Tear break up time (TBUT) and Schirmer Test 1 will be done before and after 90 days. Adherence to honey consumption will be monitored using a daily diary. This study aims to provide better understanding of the potential role of Kelulut honey as a supplementary therapy in patients with juvenile open-angle glaucoma.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 24 Jan 2026
- Start date
- 15 Jan 2026
- Primary completion date
- 15 May 2026
- Lead sponsor
- Universiti Sains Malaysia
- Diseases
- Glaucoma
- NCT number
- NCT07396441
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 60
- From 15 Jan 2026 to the primary completion date, 15 May 2026
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with allergy to honey or honey-based products OCT signal less than 6/10 Concurrent retinal diseases and other optic neuropathies Systemic neurodegenerative disease Systemic comorbidities such as diabetes mellitus and autoimmune diseases Patients on other honey-based products for the last 3 months Patient who consumes honey-based products during the study duration of 3 months (monitoring via honey-diary, return of the used sachet during the follow up visits) Patients on anti-oxidants, traditional medications or herbal products for the last 3 months Topical usage of steroids, systemic steroids and non-steroidal anti-inflammatory drugs.
Other
- Sepsis Compliance less than 75%.
Who the study is looking for
- JOAG patients age 15 years old and above until 40 years old at the time of diagnosis Compliant to conventional treatment achieved target intraocular pressure
Age in the registry: 15 years to 40 years · Sex: All · Does not accept healthy volunteers
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital Raja Perempuan Zainab II Coordinator of this site? Confirm its status | Kota Bharu | Malaysia | Recruiting |
| Hospital Sultan Ismail Petra Coordinator of this site? Confirm its status | Kuala Krai | Malaysia | Recruiting |
| Hospital Sultanah Nur Zahirah Coordinator of this site? Confirm its status | Kuala Terengganu | Malaysia | Recruiting |
| Hospital Universiti Sains Malaysia Coordinator of this site? Confirm its status | Kubang Kerian | Malaysia | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.